Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The fluocinolone acetonide implant (FAi) significantly improved vision and reduced macular swelling in non-infectious uveitic macular edema (UME). Predictive factors included prior treatment response and retinal layer appearance.
Area Of Science
- Ophthalmology
- Retinal Diseases
- Pharmacological Treatments
Background
- Non-infectious uveitic macular edema (UME) poses a significant challenge to vision.
- Previous treatments like dexamethasone implants (DEXi) may have limitations.
- Evaluating novel therapeutic options is crucial for managing chronic UME.
Purpose Of The Study
- To assess the safety and efficacy of the fluocinolone acetonide implant (FAi) in patients with chronic non-infectious UME.
- To identify predictors of treatment response to FAi after prior DEXi therapy.
- To analyze visual acuity and macular thickness changes post-FAi implantation.
Main Methods
- Retrospective, multicenter, real-world study design.
- Inclusion of patients with chronic non-infectious UME previously treated with at least two DEXi.
- Evaluation of best-corrected visual acuity (BCVA) and central macular thickness (CMT) over 12 months.
Main Results
- Significant improvements in BCVA and CMT were observed at 1, 3, 6, and 12 months post-FAi.
- Ocular hypertension occurred in 19.2% of eyes, managed with medication.
- Prior anatomical response to DEXi predicted FAi outcomes; DRIL and HRF at baseline indicated a higher need for rescue DEXi.
Conclusions
- FAi implantation demonstrated significant efficacy in improving BCVA and CMT for non-infectious UME over 12 months.
- The implant exhibited a favorable safety profile.
- Response to prior DEXi and baseline retinal characteristics (DRIL, HRF) are potential predictors of FAi treatment success.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...